Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on HAVAS SA. We currently have 4 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
Slightly slowing organic growth, although on a tough basis of comparison
26 Oct 16
Havas’ Q3 16 revenues grew by 2% organically (on a tough basis of comparison as Q3 15 was +5.5%) after +2.7% in Q2 and +3.4% in Q1, leaving the 9 months 2016 underlying top-line performance at +2.7% (9 months 2015: +6%). The Q3 organic trend was supported by Europe (+7.7%) while Asia Pacific and LatAm were down respectively 7.1% and 6.3%. The North American decline (-1.2%; 0% ytd) is said to be against a high base-line with Q4 and FY17e expected to see improvements. Reported revenues at 30 September reached €1,624m, up €74m (+4.8%) from a year earlier, and came after a €46.3m negative impact from forex (i.e. -3%) and a +5.1% impact from acquisitions (€78.4m). The FY16e guidance for top-line organic growth, which had been slightly upgraded from +2-3% to +3-4% in August is therefore more likely to be around +2.5% to +3% according to management who also said it was confident for FY17e
Slightly slowing Q2 organic growth but a solid full-year guidance
08 Aug 16
Havas’ revenues grew by 2.7% organically over Q2 16 after the +3.4% registered over Q1, leaving the H1 16 top-line organic revenue performance at a very decent +3% (Publicis: +2.8%). Reported revenues at 30 June reached €1,087m, up €53m from a year earlier, and came after a €29m negative impact from forex (i.e. -2.8%) and a +5% impact from acquisitions (€51m). Consolidated OP improved by 6.8% to €146.7m, i.e. a 20bp margin improvement to 13.5%. Group share net income amounted to €82.4m compared with €77m a year earlier. The FY16e guidance was slightly upgraded for top-line organic growth (from +2-3% to +3-4%) while reiterated for the operating margin (+10-15bp), which we estimate is underlining management’s traditional caution.
Solid top-line organic performance confirmed
23 Oct 15
After the solid H1 15 figures (organic revenue growth of +6.3%), Havas produced a satisfactory set of Q3 15 figures with revenues up 5.5% organically (despite a tough basis of comparison as Q3 14 was +6%). The 9 month performance was thus +6% (9 months 2014: +5.8%), with total reported revenues of €1,550m, up 18.1% or +€337m (including a €121m positive impact from forex). Management however maintained its previous guidance for the full-year for consolidated revenues to rise by +5% organically, implying a fairly low Q4 (c.+2%). This is, however, against a rather high basis of comparison and CEO Yannick Bolloré has stated that the macro-economic environment is not as good as three months ago, with LatAm namely deteriorating (organic growth down 0.9% over Q3). He reiterated his confidence in an improvement of around +30bps for the operating margin this year.
Impressive organic top-line performance, but modest profitability improvement
01 Sep 15
Havas has just produced solid H1 15 figures with organic revenue growth reaching +6.3%, higher than its main competitors as Publicis delivered +1.2%, WPP +4.9% and Omnicom +5.2% and despite a rather unfavourable basis of comparison (H1 14 was +5.7%). This nonetheless reflects some slowdown in Q2 to +5.5% after +7.1% in Q1. Reported revenues rose by 19.2% after a positive forex impact of €85.6m (US$ rise versus the euro) and a €20m impact from acquisitions. The operating margin improved 22bp to 13.25% (H1 14 restated figures further to the retrospective application of IFRIC 21), despite a slight negative impact from the compensation ratio (61.5% versus 61.2%, reflecting the traditional H1 impact from bonuses), as the group pursued its efforts to reduce costs (namely continuing to review all its supplier contracts and reducing its lease costs, the latter being supported by the development of the Village concept). Management reiterated its 2015 guidance (+3% organic growth; +30bp in profitability). As a reminder, Asia-Pacific and LatAm generate only 15% of total revenues, which could cushion in the short term the latter's slowdown negative impact.
N+1 Singer - Small-cap quantitative research - Momentum screen refresh + 10 focus stocks
12 Jan 17
We have refreshed our momentum style screen for the first time since inception on 26 July 2016. As before, the screen selects the 25 stocks exhibiting the most extreme momentum characteristics, according to our measurement method. From these we have selected 10 to focus on. Since inception the screen has underperformed both the main small-cap and micro-cap indices against a background of generally rising momentum. We have noted a subset of the basket, where decelerating momentum at the time of measurement appears correlated with significant share price falls since selection. We shall monitor this factor with the new screen, albeit there are only two such stocks showing this pattern, namely Lamprell (not rated) and Gear4music (not rated).
N+1 Singer - Morning Song 12-01-2017
12 Jan 17
As anticipated, the second half has again been stronger than H1 and results will be broadly in line with expectations. In line with this, the order book has continued to grow and is at record levels. This confirms that significant progress has been made in the Group’s shift towards its Technology Products division which, as targeted, contributed c.60% of group revenue in FY16. The small acquisition of Cable Power also gives a complementary boost to the product range. It is also worth noting the significant reduction in net debt, £1.0m ahead of our forecast. We remain supportive of the Group’s strategy and continue to see a bright future as this transition towards a design led technology solutions business continues. We look forward to more detail in March at the final results.
Conviction List Q1 2017
05 Jan 17
Since its inception in 2010, the Conviction List has outperformed the market in 11 of 19 periods and a reinvested Conviction List would have returned 260% against a Small Companies index that would have returned 194%. Our Conviction List returned 0.4% over the last quarter; this was set against the benchmark UK Small Companies index that returned 4.0% over the same period.
Share & share alike
11 Jan 17
Last week’s note ‘2016 AIM IPOs- Another discerning year’ *prompted further perusal of the AIM December 2016 Factsheet. With acknowledgement to BuzzFeed – we have set a simple quiz~. Which are the largest companies on AIM, which trade most and how much? It is a timely reminder that at the year end, focus remained on the FTSE 100 and larger companies, yet the prospects for smaller companies continue to be broadly positive. As the company trading statement season gets underway, the initial signs are encouraging. The tone of these updates will set the trend near term.
Small Cap Breakfast
11 Jan 17
Physiomics* (PYC.L) | Joules Group (JOUL.L) | Premier Asset Management Group (PAM.L) | Evgen Pharma (EVG.L) | Sigma Capital (SGM.L) | Caledonia Mining (CMCL.L) | Omega Diagnostics Group (ODX.L) | Vela Technologies (VELA.L) | Morses Club (MCL.L) | Hummingbird Resources (HUM.L)
What a year it was!
16 Jan 17
2016 got off to a rocky start. Not long into January, after just a few trading days, global equity markets lost more than US$4tn of value due to investor sentiment towards China’s economic slowdown and depreciating currency. This was immediately followed by a slump in the oil price. By the third week of January, Brent Crude hit its year low at $27.10 a barrel causing an immediate sell off in the energy sector. Once the Q1 dust had settled, attention turned to the UK’s vote on whether to remain a member of the EU. The Brexit vote result proved to be a genuine shock for markets, with many investors having believed that the UK would stay within the European Union. Attention soon turned to the equally ill-tempered US Presidential elections and all the political and economic unknowns that Trump’s victory has spawned. As a result, AIM, has seen a roller-coaster of a year in 2016.